• Home

• Small Molecules: Hit identification

• Small Molecules: Hit-to-Lead optimization

• Small Molecules: physicochemical properties

• Small Molecules: ADME

• Small Molecules: Toxicity

• Small Molecules: Selectivity

• Antibodies: Humanization and Optimization

• Protein Modeling. Discovery

• Protein Modeling: HERG binding

• Protein Modeling: Albumin binding

• Quantum Discussions Forum    

You access the old version of our website. Please point your browser to our new home page.

Partnerships and Collaborations

Quantum Pharmaceuticals has two main development directions: application of techniques developed in-house to drug discovery and molecular modeling and constant development of even more efficient new technologies in these areas.

Our business development directions:

- Collaboration with pharmaceuticals, cosmetics, agricultural and petro-chemical companies. We support the whole early drug discovery process from the screening of virtual libraries to the optimization of lead molecules into drug candidates or other candidates. A network of expert scientists guarantees the timely and cost-efficient performance and delivery of superior products. We value this work very highly and concentrate our efforts in order to do our job successfully .
Read more drug discovery collaborations>>>

- Participation in governmental and non-profit initiatives. Quantum Pharmaceuticals will participate in the discovery of new drugs on the basis of known 3D protein structures.
Read more >>>

- Out-licensing of lead candidates from Quantum Pharmaceuticals’ in-house drug discovery program. Currently, Quantum Pharmaceuticals is developing drug candidates for a number of protein targets for Cancer, COPD, Alzheimer's disease and AIDS.

We hope that by sharing our unique technological advances, we will be able to discover medicines that will meet medical needs and enhance the quality of life.

Our Current Partners and Collaborators:

- N.Bach Institute of Biochemistry RAS .

- A.N. Belozersky Institute of Physico-Chemical Biology.

- Russian Pulmonology Institute .

- Kurchatov Institute . Quantum Pharmaceuticals and the Russian Research Center “Kurchatov Institute” /Institute of Molecular Physics began collaboration in order to create models, which describe the collective nature of van der Waals interactions.

- Institute of Cytology RAS . Quantum Pharmaceuticals and Institute of Cytology RAS are collaborating to identify and validate prospective new protein targets for the treatment of Alzheimer's disease, Parkinson's disease, and Huntington's disease.